CMS proposes outcome‑linked payment reforms for clinical software and AI, spotlighting equity, data governance, and systemic cost drivers
Original framing: “STAT+: CMS signals intent to revamp how it pays for clinical software and AI” — STAT News
Robust scientific validation of AI tools—through randomized controlled trials, external validation, and post‑deployment monitoring—is still rare, yet it is essential for any payment model that claims to improve patient outcomes. The lack of standardized evidence pipelines currently weakens the credibility of CMS's proposed framework.
CMS's payment reform sits at the intersection of historic tech rollouts, emerging AI evidence, and entrenched power asymmetries that marginalize vulnerable patients.
By integrating Indigenous data sovereignty, cross‑cultural lessons from global health systems, and rigorous scientific validation, the policy can shift from a market‑driven incentive to a equity‑centered, outcome‑focused framework. Independent evaluation labs, community‑governed data trusts, and bundled payments tied to transparent value metrics together create a feedback loop that aligns corporate incentives with patient health. Embedding trickster insights reminds policymakers to guard against the seductive illusion of progress that masks profit extraction, ensuring that the promised benefits of AI are realized for all communities.